Clinical trials
Dermatitis, Atopic trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
179 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 11 |
| 2022 | 18 |
| 2023 | 36 |
| 2024 | 33 |
| 2025 | 30 |
| 2026 | 24 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 94 |
| Recruiting | 33 |
| Unknown status | 17 |
| Active, not recruiting | 14 |
| Not yet recruiting | 13 |
| Terminated | 4 |
| Enrolling by invitation | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Keymed Biosciences Co.Ltd | 15 |
| Sanofi | 13 |
| Pfizer | 10 |
| AbbVie | 8 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 8 |
| Jiangsu vcare pharmaceutical technology co., LTD | 7 |
| Akeso | 6 |
| Amgen | 5 |
| Shanghai Mabgeek Biotech.Co.Ltd | 5 |
| Innovent Biologics (Suzhou) Co. Ltd. | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dermatitis, Atopic | 179 |
| Eczema | 17 |
| Asthma | 7 |
| Dermatitis | 5 |
| Hypersensitivity | 4 |
| Rhinitis, Allergic | 4 |
| Immune System Diseases | 3 |
| Pulmonary Disease, Chronic Obstructive | 3 |
| Skin Diseases | 3 |
| Hidradenitis Suppurativa | 2 |
Trials
Showing 1 to 25 of 179. Each trial links to its page on Pharma Observatory.
79 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.